UF

UFP Technologies, Inc.

UFPTHealthcareNASDAQ

Medical Devices · Last scanned Sep 5, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$602.8M
+19.5% YoY
Net Income
$68.3M
+15.8% YoY
EBITDA
$111.5M
+16.4% YoY
Free Cash Flow
$34.9M

Scan Results

Daily timeframe
2 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Sep 3 RSI OversoldRSI 17.3, below 30, stock may be oversold
Sep 2CONFIRMED RSI OversoldRSI 16.9, below 30, stock may be oversold
About UFP Technologies, Inc.

UFP Technologies, Inc., together with its subsidiaries, designs and manufactures solutions for medical devices, sterile packaging, and other engineered custom products in the United States. Valued at $2.24B, UFPT is a mid-cap name in its sector. The company provides protective drapes for robotic surgery, patient handling and comfort, advanced wound care, infection prevention, disposables for surgical and endoscopic procedures, packaging for medical devices, orthopedic implants, components for cardiac implants, dispenser coils for catheters, and biopharma drug manufacturing.

Where UFPT stands vs its 150-day and 200-day moving averages

As of the September 3, 2026 close, UFPT finished 23.04% above its 150-day moving average ($237.68) and 23.53% above its 200-day moving average ($236.74). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is UFPT overbought or oversold?

At the September 3, 2026 close, UFPT's RSI(14) was 17.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$2.24B
P/E (TTM)31.02
Fwd P/E24.32
EPS$9.31
Beta1.07
52W Change+39.2%
ROE17.1%
Analysis

The company holds $9.0M in cash, though total debt stands at $136.3M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $34.9M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 17.1%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 9.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $353.8M (2022) to $602.8M (2025), reflecting a 70% increase over the period.

UFP Technologies, Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence UFP Technologies, Inc.'s trajectory.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms